^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Excerpt:
...Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors

Published date:
05/28/2020
Excerpt:
Patients with HER2-expressing or amplified advanced solid tumors refractory to standard therapies were recruited....As of October 1, 2019 among 19 patients (breast cancer, colorectal cancer and gastric cancer)treated,no one experienced dose-limiting toxicity….A166 showed an acceptable safety profile and promising anti-tumor activity in patients with HER2-expressing advanced solid tumors.
DOI:
10.1200/JCO.2020.38.15_suppl.e13007